Clinical trial registry record

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 5, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07728175
Last registry update
October 5, 2026
Status
Recruiting
Phase
Phase 1
Sponsor
University of Missouri-Columbia
Enrollment
225
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · PARALLEL · BASIC SCIENCE · TRIPLE
Evidence population
Human clinical study registration
Participants
225
Population
FEMALE · 45 Years to 65 Years
Duration
2026-12-01 to 2028-07-07
Intervention
Sirolimus (rapamycin); Placebo
Comparator
Sirolimus; Placebo
Outcomes measured
Change in Cerebral Blood Flow as measured by MRI — Baseline to 4 weeks; Measure the change in plasma Marker-cytokine using a Meso Scale Discovery (MSD) analyzer. — Baseline to 4 weeks; Measure baseline to post-treatment changes in Plasma Markers-AD pathology using a Meso Scale Discovery (MSD) analyzer —…; Measure brain function connectivity by fMRI — Baseline to 4 weeks; Measurement of blood brain barrier by MRI — Baseline to 4 weeks; Measurement of brain oxygenation by MRI — Baseline to 4 weeks; Measurement of glucose uptake in the brain by PET imaging — Baseline to 4 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON